These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

975 related articles for article (PubMed ID: 25672679)

  • 21. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients.
    Swiecicki PL; Zhen DB; Mauermann ML; Kyle RA; Zeldenrust SR; Grogan M; Dispenzieri A; Gertz MA
    Amyloid; 2015; 22(2):123-31. PubMed ID: 26017327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
    Patil MB; Ghode P; Joshi P
    Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
    Coelho T; Maurer MS; Suhr OB
    Curr Med Res Opin; 2013 Jan; 29(1):63-76. PubMed ID: 23193944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.
    Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y
    Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early diagnosis and management of patients with familial ATTR amyloidosis receiving livers from asymptomatic variant TTR carriers.
    Munar-Qués M; Viader-Farré C; Zabay-Becerril JM; Mulet-Ferrer JM
    Amyloid; 2011 Sep; 18(3):172-3. PubMed ID: 21774739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hereditary transthyretin amyloidosis caused by the rare Phe33Leu mutation.
    Björkenheim A; Szabó B; Sztaniszláv ÁJ
    BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31932463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and future treatment of amyloid neuropathies.
    Adams D; Cauquil C; Theaudin M; Rousseau A; Algalarrondo V; Slama MS
    Expert Rev Neurother; 2014 Dec; 14(12):1437-51. PubMed ID: 25416603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinctive Patterns of Transthyretin Amyloid in Salivary Tissue: A Clinicopathologic Study of 92 Patients With Amyloid-containing Minor Salivary Gland Biopsies.
    Jamet MP; Gnemmi V; Hachulla É; Dhaenens CM; Bouchindhomme B; Delattre C; Glowacki F; Hatron PY; Lacour A; Lamblin N; Launay D; Leleu X; Guiochon-Mantel A; Valleix S; Maurage CA; Copin MC; Buob D
    Am J Surg Pathol; 2015 Aug; 39(8):1035-44. PubMed ID: 25828388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.
    Yamashita T; Ueda M; Misumi Y; Masuda T; Nomura T; Tasaki M; Takamatsu K; Sasada K; Obayashi K; Matsui H; Ando Y
    J Neurol; 2018 Jan; 265(1):134-140. PubMed ID: 29177547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
    Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C
    G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
    Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations.
    Conceição I; Damy T; Romero M; Galán L; Attarian S; Luigetti M; Sadeh M; Sarafov S; Tournev I; Ueda M
    Amyloid; 2019 Mar; 26(1):3-9. PubMed ID: 30793974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Familial amyloid polyneuropathy: clinicopathological aspects].
    Koike H; Sobue G
    Brain Nerve; 2014 Jul; 66(7):749-62. PubMed ID: 24998820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN; Deeks ED
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
    Butler JS; Chan A; Costelha S; Fishman S; Willoughby JL; Borland TD; Milstein S; Foster DJ; Gonçalves P; Chen Q; Qin J; Bettencourt BR; Sah DW; Alvarez R; Rajeev KG; Manoharan M; Fitzgerald K; Meyers RE; Nochur SV; Saraiva MJ; Zimmermann TS
    Amyloid; 2016 Jun; 23(2):109-18. PubMed ID: 27033334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.
    Gopal DM; Ruberg FL; Siddiqi OK
    Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The transthyretin amyloidoses: advances in therapy.
    Dubrey S; Ackermann E; Gillmore J
    Postgrad Med J; 2015 Aug; 91(1078):439-48. PubMed ID: 26048914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current approaches for treatment of hereditary transthyretin amyloidosis (ATTR)].
    Zibert A; Hüsing-Kabar A; Schmidt H
    Dtsch Med Wochenschr; 2019 Oct; 144(20):1438-1443. PubMed ID: 31594020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.